By Colin Kellaher
AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.
AbbVie on Friday said a green light would make Rinvoq the first and only oral advanced therapy for the inflammatory disease that can cause headache, jaw pain and changes in vision, including sudden and permanent vision loss.
The North Chicago, Ill., biopharmaceutical company said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the first half of the year.
AbbVie in late January said it expects Rinvoq revenue to top $11 billion in 2027.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 28, 2025 06:34 ET (11:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。